Warberg Asset Management’s Ernexa Therapeutics Warrants ERNAW Stock Holding History

Warberg Asset Management’s Portfolio ERNAW Stock Details ERNAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.95K	Sell	69,430 -184,370	-73%	-$17.5K	﹤0.01%	157
2026 Q1	$7.11K	Buy	+253,800	New	+$15K	﹤0.01%	174

Other funds holding ERNAW

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Warberg Asset Management's ERNAW Position: Q2 2026 in Review

Warberg Asset Management reduced its Ernexa Therapeutics Warrants (ERNAW) stake by 73% in Q2 2026, selling an estimated $17.5K and leaving 69,430 shares worth $4.95K. The position accounts for ﹤0.01% of the portfolio, ranked #157.

Warberg Asset Management first reported a position in ERNAW in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.11K in Q1 2026. 6 funds tracked by Wall St. Rank hold ERNAW as of Q2 2026.

Warberg Asset Management held 69,430 shares of Ernexa Therapeutics Warrants worth $4.95K as of Q2 2026.
Warberg Asset Management sold 184,370 Ernexa Therapeutics Warrants shares in Q2 2026, an estimated $17.5K.
Ernexa Therapeutics Warrants made up ﹤0.01% of Warberg Asset Management's portfolio in Q2 2026, its #157 holding.
Warberg Asset Management first reported a position in Ernexa Therapeutics Warrants in Q1 2026 and has held it in 2 quarters since.
Warberg Asset Management's Ernexa Therapeutics Warrants position peaked at $7.11K in Q1 2026.
6 funds tracked by Wall St. Rank held Ernexa Therapeutics Warrants as of Q2 2026.

Based on Warberg Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.